Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 387

1.

How physician obesity specialists use drugs to treat obesity.

Hendricks EJ, Rothman RB, Greenway FL.

Obesity (Silver Spring). 2009 Sep;17(9):1730-5. doi: 10.1038/oby.2009.69. Epub 2009 Mar 19.

2.

Incorrect use of orlistat and sibutramine in clinical practice.

Dahlin A, Beermann B.

Eur J Clin Pharmacol. 2007 Feb;63(2):205-9. Epub 2007 Jan 5.

PMID:
17205321
3.

Treatment of obesity with "combination" pharmacotherapy.

Rothman RB.

Am J Ther. 2010 Nov-Dec;17(6):596-603. doi: 10.1097/MJT.0b013e31818e30da.

PMID:
19352140
4.

Meta-analysis: pharmacologic treatment of obesity.

Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG, Morton SC.

Ann Intern Med. 2005 Apr 5;142(7):532-46.

PMID:
15809465
5.

Pharmacologic options for the treatment of obesity.

Campbell ML, Mathys ML.

Am J Health Syst Pharm. 2001 Jul 15;58(14):1301-8. Review.

PMID:
11471477
6.

Pharmacotherapy for obesity.

Ioannides-Demos LL, Proietto J, McNeil JJ.

Drugs. 2005;65(10):1391-418. Review.

PMID:
15977970
7.

An update on the pharmacological treatment of obesity.

Schnee DM, Zaiken K, McCloskey WW.

Curr Med Res Opin. 2006 Aug;22(8):1463-74. Review.

PMID:
16870072
8.

Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis.

Neovius M, Johansson K, Rössner S.

Obes Rev. 2008 Sep;9(5):420-7. doi: 10.1111/j.1467-789X.2008.00463.x. Epub 2008 Jan 15. Review.

PMID:
18208467
9.

National trends in antiobesity medication use.

Stafford RS, Radley DC.

Arch Intern Med. 2003 May 12;163(9):1046-50.

PMID:
12742801
10.

Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats.

Roth JD, Trevaskis JL, Wilson J, Lei C, Athanacio J, Mack C, Kesty NC, Coffey T, Weyer C, Parkes DG.

Int J Obes (Lond). 2008 Aug;32(8):1201-10. doi: 10.1038/ijo.2008.91. Epub 2008 Jun 17.

PMID:
18560368
11.

Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance.

Gursoy A, Erdogan MF, Cin MO, Cesur M, Baskal N.

Eat Weight Disord. 2006 Dec;11(4):e127-32.

PMID:
17272944
12.

Pharmacological therapies for obesity.

Kaplan LM.

Gastroenterol Clin North Am. 2005 Mar;34(1):91-104. Review.

PMID:
15823441
13.

Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.

Bays H.

Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1777-801. doi: 10.1586/erc.10.125. Epub 2010 Aug 16. Review.

PMID:
20707765
14.

Weight loss medications--where do they fit in?

Dixon JB.

Aust Fam Physician. 2006 Aug;35(8):576-9. Review.

15.

Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients.

Finer N, Ryan DH, Renz CL, Hewkin AC.

Diabetes Obes Metab. 2006 Mar;8(2):206-13.

PMID:
16448525
16.

Combination phentermine/topiramate for obesity treatment in primary care: a review.

Xiong GL, Gadde KM.

Postgrad Med. 2014 Mar;126(2):110-6. doi: 10.3810/pgm.2014.03.2746. Review.

PMID:
24685974
17.

Compliance, behavior change, and weight loss with orlistat in an over-the-counter setting.

Schwartz SM, Bansal VP, Hale C, Rossi M, Engle JP.

Obesity (Silver Spring). 2008 Mar;16(3):623-9. doi: 10.1038/oby.2007.96. Epub 2008 Jan 24.

18.

Combination drugs for treating obesity.

Greenway FL, Bray GA.

Curr Diab Rep. 2010 Apr;10(2):108-15. doi: 10.1007/s11892-010-0096-4. Review.

PMID:
20425569
19.
20.

Is new drug prescribing in primary care specialist induced?

Florentinus SR, Heerdink ER, van Dijk L, Griens AM, Groenewegen PP, Leufkens HG.

BMC Health Serv Res. 2009 Jan 11;9:6. doi: 10.1186/1472-6963-9-6.

Supplemental Content

Support Center